Swarthmore College

Works
Biology Faculty Works

Biology

2021

Alternative Promoter Use Governs The Expression Of IgLON Cell
Adhesion Molecules In Histogenetic Fields Of The Embryonic
Mouse Brain
T. Jagomäe
K. Singh
M.-A. Philips
M. Jayaram
K. Seppa

See next page for additional authors
Follow this and additional works at: https://works.swarthmore.edu/fac-biology
Part of the Biology Commons

Let us know how access to these works benefits you

Recommended Citation
T. Jagomäe, K. Singh, M.-A. Philips, M. Jayaram, K. Seppa, T. Tekko, Scott F. Gilbert, E. Vasar, and K.
Lilleväli. (2021). "Alternative Promoter Use Governs The Expression Of IgLON Cell Adhesion Molecules In
Histogenetic Fields Of The Embryonic Mouse Brain". International Journal Of Molecular Sciences. Volume
22, Issue 13. DOI: 10.3390/ijms22136955
https://works.swarthmore.edu/fac-biology/628

This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is brought to you for free by Swarthmore College Libraries' Works. It has been accepted for inclusion in
Biology Faculty Works by an authorized administrator of Works. For more information, please contact
myworks@swarthmore.edu.

Authors
T. Jagomäe, K. Singh, M.-A. Philips, M. Jayaram, K. Seppa, T. Tekko, Scott F. Gilbert, E. Vasar, and K.
Lilleväli

This article is available at Works: https://works.swarthmore.edu/fac-biology/628

International Journal of

Molecular Sciences
Article

Alternative Promoter Use Governs the Expression of IgLON
Cell Adhesion Molecules in Histogenetic Fields of the
Embryonic Mouse Brain
Toomas Jagomäe 1,2,3,† , Katyayani Singh 1,2, *,† , Mari-Anne Philips 1,2 , Mohan Jayaram 1,2 , Kadri Seppa 1,2,3 ,
Triin Tekko 4 , Scott F. Gilbert 5 , Eero Vasar 1,2 and Kersti Lilleväli 1,2
1

2
3

4

5

*
†


Citation: Jagomäe, T.; Singh, K.;
Philips, M.-A.; Jayaram, M.; Seppa, K.;
Tekko, T.; Gilbert, S.F.; Vasar, E.;
Lilleväli, K. Alternative Promoter Use
Governs the Expression of IgLON
Cell Adhesion Molecules in
Histogenetic Fields of the Embryonic
Mouse Brain. Int. J. Mol. Sci. 2021, 22,
6955. https://doi.org/10.3390/
ijms22136955
Academic Editor: Melitta Schachner
Received: 10 May 2021
Accepted: 23 June 2021

Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu,
19 Ravila Street, 50411 Tartu, Estonia; toomas.jagomae@gmail.com (T.J.); marianne.philips@ut.ee (M.-A.P.);
jmohan80@gmail.com (M.J.); kadriseppa@gmail.com (K.S.); eero.vasar@ut.ee (E.V.);
kersti.lillevali@ut.ee (K.L.)
Centre of Excellence in Genomics and Translational Medicine, University of Tartu, 50090 Tartu, Estonia
Laboratory Animal Centre, Institute of Biomedicine and Translational Medicine, University of Tartu,
14B Ravila Street, 50411 Tartu, Estonia
The Instituto Gulbenkian de Ciência, Rua da Quinta Grande 6, 2780-156 Oeiras, Portugal;
ttekko@igc.gulbenkian.pt
Department of Biology, Swarthmore College, Swarthmore, PA 19081, USA; sgilber1@swarthmore.edu
Correspondence: katyayani.micro@gmail.com; Tel.: +372-7374-335
These authors have contributed equally to this work.

Abstract: The members of the IgLON superfamily of cell adhesion molecules facilitate fundamental
cellular communication during brain development, maintain functional brain circuitry, and are
associated with several neuropsychiatric disorders such as depression, autism, schizophrenia, and
intellectual disabilities. Usage of alternative promoter-specific 1a and 1b mRNA isoforms in Lsamp,
Opcml, Ntm, and the single promoter of Negr1 in the mouse and human brain has been previously
described. To determine the precise spatiotemporal expression dynamics of Lsamp, Opcml, Ntm
isoforms, and Negr1, in the developing brain, we generated isoform-specific RNA probes and carried
out in situ hybridization in the developing (embryonic, E10.5, E11.5, 13.5, 17; postnatal, P0) and adult
mouse brains. We show that promoter-specific expression of IgLONs is established early during
pallial development (at E10.5), where it remains throughout its differentiation through adulthood. In
the diencephalon, midbrain, and hindbrain, strong expression patterns are initiated a few days later
and begin fading after birth, being only faintly expressed during adulthood. Thus, the expression of
specific IgLONs in the developing brain may provide the means for regionally specific functionality
as well as for specific regional vulnerabilities. The current study will therefore improve the understanding of how IgLON genes are implicated in the development of neuropsychiatric disorders.
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The first sign of vertebrate brain development is the appearance of the neural plate,
which gives rise to neuroepithelial cells (NECs), the precursors of neural progenitor cells
(NPCs). Early histogenetic processes of neural tissue formation encompasses massive
proliferation and migration of progenitor cells, followed by neuronal differentiation together with neuritogenesis and axon guidance to appropriate targets for creating synaptic
connections [1–3]. These processes are highly coordinated by spatiotemporal crosstalk of
signaling cues and gene regulatory pathways, accounting for proteome diversifications by
generating multiple alternative mRNA isoforms [4–7]. Cell adhesion molecules function as
key elements for all these developmental milestones.
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Members of neuronal cell adhesion molecules of the IgLON superfamily, LSAMP, (limbic system associated membrane proteins), NTM (neurotrimin), OPCML (opioid-binding
cell adhesion molecule), harbor two alternative promoters (1a and 1b), leading to transcripts
that encode proteins with alternative N-terminal sequences. Other members, NEGR1 and
IgLON5 have instead a single promoter [8,9]. The IgLON superfamily of brain glycoproteins carry three Ig domains and are anchored to neural and oligodendrocyte cell
membranes by glycosylphosphatidylinositol (GPI) [10,11]. Homophilic and heterophilic
intra-family interactions of IgLONs on the plane of cell membranes can modify the contextdependent functional aspects of neural development, maintenance, and plasticity [12–22].
In humans, several polymorphisms at IgLON loci and imbalances in IgLON expression
levels are associated with cognitive ability andwide variety of neuropsychiatric disorders,
such as schizophrenia, major depression, bipolar disorder, and autism [23–28]. Specific
phenotypes appear to be influenced by all IgLON genes. For example, autism has been
shown to be linked with the loci of NEGR1 [29] NTM/OPCML [30] and LSAMP [31]. Similarly, differences in cognitive ability have been associated with NEGR1 [32] and the loci of
all IgLONs significantly associate with the educational attainment [33].
Genetic deficiencies of Lsamp, Ntm, Negr1 in mice result in early developmental anomalies due to defects of corticogenesis, neuritogenesis, axon guidance, myelinization, as well
as adult abnormalities of neurogenesis and maintenance [11,17,20–22,34]. Lsamp-deficient
mice have alterations in neurotransmitter regulation, including the increased activity of
the serotonergic system, imbalanced GABAA receptors activity, as well as decreased sensitivity towards amphetamine, a condition that is also found in other IgLON deficient
mice (Ntm and Lsamp/Ntm double-mutant mice) [20,35–40]. Behavioral studies performed
with Lsamp, Ntm, Negr1 and double Lsamp/Ntm deficient mice showed impairment of
locomotor, cognition, mood and social behavior [37–42]. Moreover, Negr1 deficiency in
mice produces significant volumetric changes in the brain morphology, including decreased brain size, ventricular enlargement and the depletion of hippocampal parvalbumin
(PV)+ neurons [34,42]. The above characteristics of IgLON deficiencies in mice are very
similar to those of people with certain neuropsychiatric patients and can serve as model
endophenotypes for these conditions.
Our qPCR-based studies on the adult mouse brain have demonstrated differential
and largely complementary expression profiles driven by alternative promoters of Lsamp,
Ntm, and Opcml genes [1,4,9]. So far, promoter-specific neuroanatomical expression has
been characterized only for Lsamp, showing that alternative promoters (1a and 1b) are
employed differentially, with few overlapping areas from embryonic age E12.5 and that
they help regulate emotional and social behaviors. The 1a isoform is abundant in the
classic limbic structures such as the hippocampus, amygdala, and the caudal subgroup of
raphe nuclei, whereas the 1b isoform is expressed in the thalamic sensory nuclei, isocortical
sensory areas, and in medial raphe nuclei [39,41].Alternative promoter-specificIgLONs
expression profiles were also studied in the dorsolateral prefrontal cortex (DLPFC) of
patients with schizophrenia in the autopsy samples, and altered expression levels from
Ntm 1a, 1b isoforms and Negr1 have been reported [28].
Despite the potentially important role of IgLONs in establishing functional neural
circuits, little is known about the spatial and temporal expression of alternative promoterspecific patterns in the embryonic and postnatal brain. Therefore, to investigate the spatial
expression from Negr1, as well as from the two alternative promoters of the Lsamp, Ntm,
and Opcml, isoform-specific probes for in situ hybridization were used to label the IgLON
mRNA expression patterns in developing mouse brain. Our data show an early onset of
IgLON expression at E10.5, the time when active neuroepithelial expansion, neurogenesis,
and neuronal migration occur. Each member of the IgLON superfamily appears in the
embryonic brain in a characteristic dynamic pattern that closely approximates its adult
distribution in the central nervous system (CNS).
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2. Results
2.1. Initiation of the Expression of IgLON Members in the Early Embryonic Mouse Brain (E10–13)
The first sign of the expression of Lsamp, Negr1, Ntm, and Opcml in the CNS coincided
in mid gestational stages, at the time when active neurogenesis and neuronal migration
occurs. Prior to the neuroepithelium entering its massive neurogenesis phase at E10.5,
expression is already observable for Lsamp 1a, Negr1, Ntm 1a, and Opcml 1b in the neural
tube, ventricular zone, and around the ventricular vesicles (Supplementary Figure S1).
Whole-mount insituhybridization of E11.5 embryos shows persistent expression of IgLONs
at E11.5 in the dorsal part of developing brain vesicles (Figure 1A–N). Intense signal is
observable in telencephalic vesicles (Figure 1A–G) and at the level of pontine flexure
(Figure 1A–H). Segmental expression of Lsamp 1a (Figure 1H), Ntm 1a, Ntm 1b, Opcml 1a
and Opcml 1b (Figure 1K–N) lies bilaterally along developing neural tube, whereas the
expression of Lsampuni (Figure 1I), Negr1 (Figure 1J), and Opcml 1a (Figure 1M) is observable
at the level of the limbs. Expression of IgLONs from alternative promoters lies ventrally in
the pharyngeal pouches fading in the dorsal direction. From all observed probes, Lsamp,
Ntm and Negr1 gave positive signal in the developing inner ear (Figure 1A–E). Faint signal
is seen in presumptive trigeminal ganglion with Lsamp 1a/uni, Ntm 1a and Opcml 1b probes
(Figure 1A,B,E,G).

Figure 1. Expression of IgLON family alternative promoters at E11.5. Expression of Lsamp 1a, Lsampuni, Negr1, Ntm 1a,
Ntm 1b, Opcml 1a, and Opcml 1b mRNA was detected by whole-mount in situ hybridization of wild-type embryos. (A–G)
lateral and (H–N) dorsal views of whole-embryos. Observed mRNA expression is seen bilaterally (H,I,K,L) along neural
tube or (J,M,N) at the level of limbs. All observed mRNA probes are expressed in forebrain region and pharyngeal arches.
(A–E) specific expression of corresponding probes is seen in the developing inner ear. (A,B,E,G). Faint expression is seen
(A,B,E,G) inside and around the developing eye. Scale bar: 1 mm.

2.1.1. Forebrain (E13.5)
At E13.5 the presence of all IgLON transcripts is observed in the dorsal pallium in a
ventricular-subventricular descending gradient. The expression patterns of Lsamp 1a/uni
are overlapping and detected in the ventricular/subventricular zone of dorsal, ventral and
lateral pallium (Figure 2A,B,D,E). A faint signal is seen as a column extending from the
corner of the lateral ventricle to the pial side of the presumptive insular/piriform cortices
and pallial amygdala (Figure 2B,E and Figure 3A,B). As with Lsamp 1a and uni probes,
the Ntm 1a/1b probes are detected in the ventricular and subventricular zone (SVZ) of
dorsal, ventral and lateral pallium (Figure 2G,H,J,K). However, moving from the dorsal
pallium towards the lateral pallium, the expression pattern splits distinctively into two
separate/different domains, forming a crescent shape in the SVZ of the putative lateral and
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ventral pallium (Figure 2H,K). A similar, but fainter, column of expression is also observed
from the ventricular zone of lateral and ventral pallium to the pial side (Figure 2H,K and
Figure 3C,D).

Figure 2. Expression from IgLON alternative promoters in E13.5 mouse CNS. Whole-mount in situ mRNA hybridization.
(A,D,G,J,M,P,S) coronal sections through caudal telencephalon and (B,E,H,K,N,Q,T) telencephalon at intermediate level
through interventricular foramen (laterally), showing preoptic area, hypothalamus and diencephalon (medial portions).
All observed IgLON transcripts are present in DP from ventricular to pial surface along the rostral-caudal axis; Negr1 and
Opcml 1b give strong signal also in LP. (C,F) Lsamp 1a/uni expression is seen dorso-laterally in developing sensory input
area of sc while Lsampuni marks the roof plate. (I,L) Ntm 1a and 1b occupy the dorsal portion of the neural tube rather
complementary: Ntm 1a is strongly expressed below the Ntm 1b domain. (O) weak uniform Opcml 1a signal is detectable
through the developing sc, being somewhat stronger in the motor region (R) Opcml 1b occupies the lateral portion of sc.
(U) Negr1 expression is complementary to (C,F) Lsamp 1a/uni with the exception seen at roof plate. (V–X) schemes of cutting
planes. Abbreviations: sc, spinal cord; DP, dorsal pallium; LP, lateral pallium; VP, ventral pallium; lge, lateral ganglionic
eminence; Lsampuni (Lsamp 1a + 1b); LV, lateral ventricle; 3V, third ventricle; drg, dorsal root ganglion. Scale bar: 1 mm.

A strong signal from Ntm 1a/1b probes is seen in the pial side of the developing
insular/piriform cortices (Figure 2H,K), and signals from Opcml 1a/1b probes are observable
in the ventricular/subventricular zone of the pallium (Figure 2M,N,P,Q and Figure 3E,F). A
similar expression pattern continues in the lateral ganglionic eminence (Figure 2N,Q). Here,
a uniform Opcml 1a/1b signal is restricted to the lateral ganglionic eminence (Figure 2N,Q),
while columns of faint expression of Opcml 1a/1b bordering the lateral ganglionic eminence
appear migrating ventro-laterally towards the pial side (Figure 2M,N).
In the pial side of the developing lateral and ventral pallium, the signal of Opcml 1b
becomes intense (Figures 2Q and 3F). Negr1 is expressed in the ventricular/subventricular
zone of dorsal pallium (Figure 2S,T and Figure 3G). On the pial side of ventral and lateral pallium the expression of Negr1 appears especially strong and opposes the ventricular/subventricular zone by forming a crescent in the pallium/subpallium boundary.
Ventrally, Negr1 expression continuously lines the pial side of the allocortex (Figure 2T).
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Figure 3. In situ mRNA hybridization displaying IgLON members in developing pallium.
(A–G) Expression of IgLON probes recapitulating alternative promoter activity in pallial divisions
at E13.5 mouse embryo. (H) scheme of cutting planes. Abbreviations: DP, dorsal pallium; LP, lateral pallium; VP, ventral pallium; MP, medial pallium; lv, lateral ventricle; LGE, lateral ganglionic
eminence; MGE, medial ganglionic eminence; Lsampuni, Lsamp 1a + 1b. Scale bar: 500 µm.

2.1.2. Midbrain and Spinal Cord (E13.5)
In the developing midbrain, faint-to-medium level expression patterns of all the
IgLON transcripts are detectable in the dorso-rostral part of neuroepithelium surrounding
the 3rd ventricle (Figure 2A,D,G,J,M,P,S). All IgLON transcripts appear in the developing
spinal cord (sc) in distinct regions: Lsamp 1a/uni expression is seen dorso-laterally in
the developing sensory input area of sc, and the roof plate is marked strongly by uni
(Figure 2C,F); Ntm 1a and 1b occupy dorsal the portion of neural tube in a complementary
manner: Ntm 1a is strongly expressed immediately below the laterally positioned Ntm
1b-positive domain (Figure 2I,L). Different isoform expression patterns are also detectable
with Opcml: while uniform Opcml 1a signal is detectable throughout the developing
sc, being somewhat stronger in the motor region, the Opcml 1b transcript occupies the
lateral portion of sc (Figure 2O,R). Negr1 is strongly expressed in the dorsolateral domain
of developing sc, being complementary to Lsamp 1a/uni with the exception seen at the
roof plate (Figure 2U,C,F). In addition to their neural expression, there are also clear
signals of Lsamp 1a/uni, Ntm 1a, Opcml 1a and Negr1 in above and dorsolateral spinal cord
(Figure 2C,F,I,L,O,U).
2.2. The Expression Dynamics of IgLON Members in the Perinatal Stages (E17, P0)
Expression of IgLON members is established in most primordial brain structures at
E17, coinciding with formation and stabilization of neural circuits. Signals from IgLON
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probes form distinct but overlapping domains within developing structures. Here, the
expression patterns from alternative promoters of Lsamp, Ntm, and Opcml are principally
complementary. As the brain matures, the IgLON expression patterns are maintained in
their original locations.
2.2.1. Cerebral Cortex and Hippocampus
At E17, neurogenesis of the outermost layers of cortical plate is just ending and
neuronal morphogenesis and migration occurs.At this critical developmental stage, all
IgLON transcripts are abundantly present in the forming neocortex. Presence of IgLON
transcripts is summarized in Table 1.
Table 1. Relative abundance of IgLON transcripts in developing cortex and hippocampus at E17 and P0. Expression
abundance is determined after mRNA hybridization by visual observation as +—weak; ++—moderate; +++—strong;
—-absent. Relative abundance is not comparable between different transcripts. Lsamp 1b*—X-Gal staining. Abbreviations:
CA, cornuammonis; CP, cortical plate; DG, dentate gyrus; IZ, intermediate zone, MZ, marginal zone; L, presumptive cortical
layers; SVZ, subventricular zone; SP, subplate; VZ, ventricular zone.
Lateral Neocortex and Hippocampus at the Level of Olfactory Tuberculum and Septum
CP
MZ (L1)

Lsamp 1a
Lsamp 1b*
Ntm 1a
Ntm 1b
Opcml 1a
Opcml 1b
Negr1

OUTER (L2/3)

Hippocampus
MIDDLE
(L4—6)

SP (L6B)

IZ

SVZ

VZ

CA

DG

E17

P0

E17

P0

E17

P0

E17

P0

E17

E17

E17

E17

P0

E17

P0

+
+++
+

+++
+
+
+++
+++
-

+++
++
+++
+++
+++
+++

+
+++
+++
++
+++
+++
++

+
++
++
++
++
++
+++

+
++
+++
+
++
+
++

++
+
+
+
+
+++

++
+
++
+

+
-

+
+
+
+
+++

+
+
+
+

+
+
+
+++
+
++

+++
+
+
+++
+
+

+
+
+
+
+

++
++
+

Markedly, the expression of Lsamp 1a shows labeling below the marginal zone of insula
and neocortex, where it delineates the subplate region (future layer Vib) (Figure 4A–C). The
expression of Lsamp 1a is observed in the subventricular zone of the neocortex (Figure 4A,B),
while Lsamp 1b expression pattern is localized into the cortical plate of presumptive barrel
cortex (Figure 4D–F) and shows labeling of both the insula and neocortex, but not claustrum.
At P0, the expression of Lsamp 1a is mainly restricted to layer 1 of the neocortex, except
at the medial cingulate cortex, where labeling extends weakly from subiculum to CA1
(Figure 5A–C). Localization pattern of Lsamp 1b is extended dorsally and additionally to
the upper layers of the neocortex.
At E17, Ntm transcripts are expressed continuously from Pir to the developing hippocampus, where the expression domain is narrower in width and exhibits an outsideinside strength gradient (Figure 4G–L, Supplementary Figure S2). This signal, however, is
absent from the marginal zone. Expression of Ntm 1a shows superficial insular labeling
(Figure 4G). Meanwhile cortical labeling stops medially at the parahippocampal subiculum
(Figure 4G–I). The Ntm 1b transcript is more enriched laterally, whereas only a weak signal
is detectable in the developing hippocampus (Figure 4J–L, Supplementary Figure S2).
Expression of Ntm 1a at P0, shows a relatively strong signal throughout the developing
sensory and motor cortices (Figure 5G–H), where the continuous expression from the
subiculum to the hippocampus weakens and disappears in the presumptive CA3 region
(Figure 5H,I). The pattern of Ntm 1b is similar to 1a transcript at P0 (Figure 5K,L).
At E17.5 Opcml 1a is detected throughout the developing cortex, and the signal extends
from Pir continuously to subiculum and CA regions of the developing hippocampus
(Figure 4M,N, Supplementary Figure S2). The Opmcl 1b signal extends throughout the
entire width of cortical plate, being stronger laterally (Figure 4P–R). Opcml 1b extends into
CA fields, but not into the DG (Figure 4Q,R, Supplementary Figure S2). In the newborn
(P0) mouse cortex, the expression of Opcml 1a resembles the expression at E17, although
medio-lateral and dorso-ventral gradients are appearing (Figure 5M–O). Expression of
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Opcml 1b in the developing cortex is shifted towards upper layers (Figure 5P–R) and is
clearly defined in layer 6b (Figure 5Q).
Negr1 expression in the cortical plate declines from anterior to posterior and lateral to
medial. Negr1 is seen in the subventricular zone of dorsal pallium. We also observe strong
expression in the layer 6b continuous with the claustrum/insula (Figure 4S–U). Distinct
labeling is also seen in the dorsal endopiriform nucleus, deep to the presumptive olfactory
cortex. Expression of Negr1 at P0 remains relatively similar to embryonic stages, although
labeling in the first layer has disappeared.

Figure 4. Expression from IgLON alternative promoters at E17 mouse CNS. (A–C;G–U) In situ mRNA hybridization; (D–F)
X-gal staining. (A,D,G,J,M,P,S) coronal sections through the level of olfactory tuberculum and septum. (B,E,H,K,N,Q,T)
sections pass through the middle part of Amy and diencephalon; (C,F,I,L,O,R,U) through the caudal part of Amy and
diencephalon. Lsamp 1a is strongly expressed laterally in upper layers of neo- and allocortex as well as in subplate region;
the expression is seen in developing CPu, Amy; and thalamic nuclei. (D–F) Overall the expressions of Lsamp 1a and 1b
are largely complementary: Lsamp 1b expression is visible at the ventral portion of lateral ventricles and moving caudally,
lines the third ventricle. (G–I) Ntm 1a and (J–L) Ntm 1b are strongly detected at upper layers of the developing cortex.
(G) in CPu, Ntm 1a is seen laterally beneath the developing white matter, whereas (J) Ntm 1b is seen in the more internal
part of CPu. Strongest expression of (H,I) Ntm 1a and (K,L) Ntm 1b is seen in thalamic nuclei. Unlike Ntm 1a (K,L) the
expression of Ntm 1b is observable in Amy. (M–O) Opcml 1a is broadly expressed in developing cortex and hippocampus;
however (P–R) Opcml 1b is restricted to dorsolateral cortex with gradient starting from developing 2/3 layer. (N,O) Opcml
1a expression in thalamic and hypothalamic nuclei is complementary to (Q,R) Opcml 1b. (S–U) Negr1 is broadly expressed
in the lateral region of the developing cortex, excluding the uppermost layer, and in the dorsal part of LV ventricular zone.
(T,U) strong expression is seen throughout Amy and Th. (V–X) schemes of cutting planes. Abbreviations: 3V, third ventricle;
Amy, amygdala; CPu, caudal putamen; LV, lateral ventricle; MS, medial septum; Ncx, neocortex; Pir, piriform cortex; Th,
thalamus; Hy, hypothalamus. Scale bar: 1 mm.

2.2.2. Subcortical Structures and Diencephalon
Lsamp 1a at E17 labels the transition between CPu and ventral striatum continuously
with the lateral and dorsal part of the striatum (Figure 4A). Expression in the thalamus
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is mainly periventricular (Figure 4B,C) with some indication of pre-thalamic positive
elements above the peduncle (Figure 4C, Supplementary Figure S2). Expression of Lsamp
1a is also seen at the ventromedial hypothalamic nucleus (VMH) (Figure 4C). Lsamp 1b
expression emerges from the ventricular zone of subpallium extending caudally around
the third ventricle (Figure 4D–F). Dense labeling of the dorsal endopiriform nucleus is
also seen (Figure 4D). At P0 Lsamp 1a seems restricted to intralaminar thalamic elements
and to the parafascicular nucleus avoiding the retroflex tract (Figure 5A–C). At both
perinatal stages, the expression of Lsamp 1a appears in the striatum, pallial- and medial
amygdala (Figure 4B,C and Figure 5B). Lsamp 1b expression at P0 is maintained as in E17
(Figure 5D–F).

Figure 5. Expression from IgLON alternative promoters at P0 mouse CNS. (A–C; G–U) In situ mRNA hybridization; (D–F)
X-gal staining. (A,D,G,J,M,P,S) coronal sections through the level of olfactory tuberculum and septum. (B,E,H,K,N,Q,T)
sections pass through the middle part of Amy and diencephalon; (C,F,I,L,O,R,U) through the caudal part of Amy and
diencephalon. (A–C) Lsamp 1a is expressed laterally in the upper layer of the cortex and in the ammon horns of the
hippocampus. Expression in CPu forms a medio-lateral gradient where the strongest expression is seen medially. Strong
expression is seen in Amy. (D–F) Lsamp 1b in the cortex is seen below 1a expression domain and is missing from Amy.
(E,F) expression of Lsamp 1b persists around the third ventricle. (G–I) Ntm 1a in cortical layers is broad and forms gradient
being strongest at dorso-medial side. Strong expression is seen in Pir. Same pattern is seen with (J,K) Ntm 1b; however, the
expression is more restricted to upper layers of cortex. (G,J) in striatum Ntm 1a/1b is seen laterally immediately beneath
the developing corpus callosum. Complementary expression of (H,I) Ntm 1a and (K,L) Ntm 1b is revealed in thalamic
nuclei and Amy. (M–O) Opcml 1a is broadly expressed in the cortex, being strongest in the hippocampus. (P–R) Opcml 1b is
restricted to the dorsolateral surface of the cortex and portion of thalamic nuclei. (S–U) Negr1 is broadly expressed in lateral
surface of developing neo- and piriform cortex; (U) Negr1 expression in hippocampus is observable at caudal portion and is
(T,U) strong in Amy and upper thalamic nuclei. (V–X) schemes of cutting planes. Abbreviations: Amy, amygdala; CA1,
cornuammonis region 1; DG, dentate gyrus; CPu, caudal putamen; LV, lateral ventricle; Ncx, neocortex; Pir, piriform cortex;
Th, thalamus; Hy, hypothalamus. Scale bar: 1 mm.

At E17 Ntm 1a expression is seen as a latero-medial gradient in the lateral part of
CPu (Figure 4G). Extensive labeling is observable in the thalamus, except for the lateral
geniculate nucleus at the surface (Figure 4H,I). Expression is also seen in prethalamus
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elements and intergeniculate nucleus (Figure 4H,I). Although Ntm 1a is absent from amygdala (Figure 4G–I) the signal of Ntm 1b is detectable in the pallial and medial amygdala
at E17 (Figure 4K,L) and P0 (Figure 5K,L). At E17 Ntm 1b expression in the CPu is complementary to Ntm 1a, absent laterally (Figure 4J). Ntm 1b shows a similar prethalamic
expression pattern, although the superficial pre-geniculate nucleus is positive (Figure 4K–L,
Supplementary Figure S2). At P0 Ntm 1b expression in the CPu forms a lateral to medial
gradient (Figure 5G,J).
Opcml 1a at E17 is expressed primarily in the superficial thalamus as well as in the
medial Hb (Figure 4N, Supplementary Figure S2). Staining is seen at VMH nucleus
and superficially in the optic tract (Figure 4O). Expression of Opcml 1b shows subpial
labeling along the optic tract and the presumptive arcuate nucleus (Figure 4Q,R). Expression of Opcml 1b invades medially to the olfactory tuberculum (Figure 4Q). Expression
of Opcml 1b is prominent in the reticular-, ventromedial- and lateral thalamic nuclei at
E17 (Figure 4Q,R) and remains in the reticular- and ventromedial thalamic nuclei at P0
(Figure 5Q,R, Supplementary Figure S2). Strong expression of Opcml 1b is seen in the peduncle and thalamic nuclei avoiding the domains positive for Opcml 1a (Figure 4P–R).
Expression of Opcml 1a/1b in the CPu resembles that of Ntm 1a/1b (Figure 4M,P). The
expression of Opcml 1a at E17 is localized diffusely in the presumptive amygdala region
(Figure 4N,O, Supplementary Figure S2), whereas at P0 is expressed in the basolateral and
lateral amygdala (Figure 5N,O). Opcml 1b maintains broad expression in the pallial amygdala at E17 (Figure 4R) and becomes concentrated to specific nuclei at P0 (Figure 5P,Q).
Negr1 expression at E17 ascends above the lateral angle of the lateral ventricle, becoming strongest in the lateral septum (Figure 4S,T). Expression in the mantle of the ventral
pallium is limited medially by the pallial-subpallial boundary and extends into the pallial
amygdala (Figure 4T). At P0, the expression of Negr1 covers the cortical, basolateral, medial,
and basomedial amygdala (Figure 5S–U). At E17, the prethalamic subgeniculate and zona
incerta formations are distinctly positive just above the peduncle leaving the pregeniculate
nucleus negative (Figure 4T,U). Strong expression is observable at the dorsal, medial and
basolateral thalamic complexes (Figure 4T,U and Figure 5T,U).
2.3. The Expression of IgLON Members in the Adult Mouse Brain
2.3.1. Cerebral Cortex and Hippocampus
The adult brain expression pattern of Lsamp1a, 1b and uni is described previously
by [39]. In the adult brain, the expression of Ntm 1a is observed throughout the cortical
layers, being stronger in upper borders of 2/3 and IV (Figure 6A–C). At the level of septum
and anterior commissure, expression of Ntm 1a is evident in the barrel and motor cortices,
whereas faint expression is seen in the sensory region of cortex (Figure 6A). In contrast to
Ntm 1a, expression of Ntm 1b is clearly visible in the barrel cortex, with weak or no expression in the sensory and motor regions (Figure 6D). The expression of Ntm 1b is enriched in
upper layers of barrel, visual and auditory regions (Figure 6E,F). Ntm 1a displays uniform
expression in piriform cortex, Ectorhinal and Entorhinal (Figure 6A–C) whereas strong
expression of Ntm 1b is seen in Pir and Ent (Figure 6D–F). In the hippocampus, Ntm 1a
expression is enriched in CA1 while a relatively weak signal is observable in CA2, CA3
and DG (Figure 6B,C). A strong signal of Ntm 1b is evident rostrally in CA and DG and
fragments in caudal direction (Figure 6E,F).
Opcml 1a is observable throughout cortical layers 2–6, being intense at borders
(Figure 6G–I), while Opcml 1b is restricted to the sensory cortex and forms a gradient
inverse to Opcml 1a, being stronger in the middle layers (Figure 6J–L). Although Opcml 1a is
weak in Pir, Ect and Ent (Figure 6G–I), intense staining of Opcml 1b in these areas was seen
(Figure 6J–L). The expression of Opcml 1a is seen throughout the hippocampal structures,
being strongest in CA3 (Figure 6H,I), while hippocampal expression of Opcml 1b forms
homogeneously dispersed puncta in CA and DG (Figure 6K,L).
In the adult brain, Negr1-expressing cells are observable throughout the sensory, motor,
and visual cortices, while excluding the first layer (Figure 6M–O). The strongest signal
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is detectable in borders of the II/III layer, particularly in the barrel and auditory cortex
(Figure 6M–O). Expression is observable in CA and DG of hippocampus exceptionally
dominating in CA2 and DG regions (Figure 6N–R). The expression of Ntm 1b, Opcml 1b,
and Negr1 is maintained at layer 6b.

Figure 6. Expression from IgLON alternative promoters in the adult mouse CNS. In situ mRNA hybridization. (A,D,G,J,M)
coronal sections through the level of olfactory tuberculum and septum. (B,E,H,K,N) sections through the middle part
of Amy and diencephalon region. (C,F,I,L,O) caudal sections illustrate the mammillary hypothalamic region. (A) Ntm
1a expression is seen in Pir and anterior nuclei of thalamusas well as defined layers of sensory and motor cortex. (B,C)
Observable Ntm 1a expression pattern is seen in visual and auditory cortex and ecto- and entorhinal cortices. Relatively
strong expression is seen in amygdala as well as in specific cells of the hippocampus. (D,E) Similar expression pattern is
seen with Ntm 1b probe, where strong expression is defined in the auditory cortex and amygdala. (G,H) Opcml 1a is broadly
expressed in the cortex and strongest at upper layers throughout sensory and motor columns. Intense staining is seen in
(G) piriform cortex and (H,I) hippocampus. Similarly (J–L) Opcml 1b is restricted to the upper layers of the sensory cortex.
Strongest expression is seen in (J) piriform cortex. Faint expression is seen in (K,L) hippocampus. (M,N) Negr1 is broadly
expressed in sensory cortical structures, notably in layers of the auditory cortex. Intense expression is seen in (M) piriformand entorhinal cortex. (N,O) Relatively strong signal is seen in the hippocampus, notably in CA2 and dentate gyrus. Strong
expression in amygdala greatly overlaps with other family members. Faint expression is observable in thalamic nuclei.
(P–R) schemes of cutting planes. Abbreviations: 3V, third ventricle; Amy, amygdala; Au, auditory cortex; B, barrel cortex;
CA1, cornuammonis region 1; CA3, cornuammonis region 3; CPu, caudal putamen; DG, dentate gyrus; Ect, entorhinal cortex;
Ent, entorhinal cortex; LV, lateral ventricle; MS, medial septum; Ncx, neocortex; Pir, piriform cortex; Th, thalamus; Hy,
hypothalamus. Scale bar: 1 mm.

2.3.2. Subcortical Structures and Diencephalon
Caudal sections of Ntm 1a/1b and Opcml 1a/1b (Figure 6C,F,I,L) illustrate mamillary
hypothalamic regions with a different contour. Transcripts of both Ntm 1a and 1b are
ubiquitously present in most of the brain structures. Expression of Ntm 1a and Ntm 1b
is diffusely localized to cortical and extended nuclei of amygdala (Figure 6B,C,E,F). In
the rostral part of CPu Ntm 1a keeps dorso-ventral (Figure 6A) and Ntm 1b medio-lateral
(Figure 6D) descending gradients.
Expression of Ntm 1a and 1b specifically avoids claustrum. Although Ntm 1b expression in thalamus and hypothalamus is seen as scattered puncta (Figure 6E,F), the expression
of Ntm 1a diffuses from the centrolateral, centromedial, paracentral, rhomboid, reuniens
thalamic nuclei to the subincertal nucleus (Figure 6B). Diffuse expression of Ntm 1a is
also observable in the dorsal part of anterior pretectal nucleus and covers both the dorsal
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and ventral zona incerta (Figure 6C). Strong Ntm 1a expression is seen in the mamillary
hypothalamic region (Figure 6C). Distinct expressions of Ntm 1a and 1b are seen in habenula
and paraventricular thalamic nuclei (Figure 6B,E).
Transcripts of Opcml 1a and 1b are absent from the CPu and are expressed only
weakly in regions of thalamus and hypothalamus. The mamillary hypothalamic region
and habenula are positive for Opcml 1a (Figure 6H). In the amygdala, Opcml 1a is prominently expressed in basolateral nuclei, with weaker expression in the cortical amygdala
(Figure 6H,I). Opcml 1b is absent in basolateral amygdala and only weakly expressed in
the cortical amygdala (Figure 6K,L).
Negr1 expression is absent or weak in CPu and strongly where the CPu transitions
to the extended amygdala (Figure 6M,N). Distinct expression is seen in the hypothalamic
nuclei (Figure 6M). Expression of Negr1 covers the entire amygdala, being weakest in the
basolateral nucleus (Figure 6N). Moderate expression is detectable in habenula and around
mammillary recess of the third ventricle (Figure 6N).
2.3.3. Cerebellum
The complementary expression pattern of IgLON members is clear in adult cerebellum
(Figure 7). The expression of the Lsamp 1a isoform is not detectable (Figure 7A). However,
Lsamp 1b expression is seen with X-Gal staining in the proximal segment of the molecular
layer and invades through distinct cells in the Purkinje- and granular cell layer into the
white matter (Figure 7B). Strong expression of Ntm 1a clearly delineates the Purkinje cell
layer and is observable in specific cells of granular cell layer (Figure 7D). An intense Ntm
1b signal is evident only in granular cell layers (Figure 7E). The localization of Opcml 1a
and 1b transcripts occupies Purkinje and granular cell layers (Figure 7G,H,J). Weak labeling
with Opcml 1a probe is evident in the molecular layer (Figure 7G). The Negr1 signal is
pronounced in the Purkinje cell layer and granular cell layer (Figure 7K). Immunostaining
with antibodies raised against Lsamp, Ntm, and Opcml shows punctuated localization
in the Purkinje and molecular cell layer (Figure 7C,F,I). Immunohistochemical staining
of Negr1 shows strong staining of Purkinje cells and punctuated staining throughout the
cerebellum (Figure 7L).
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Figure 7. Expression from IgLON alternative promoters and proteins in adult mouse cerebellum.
(A,D–E,G,H,K) in situ mRNA hybridization; (B) X-gal staining; (C,F,I,L) immunofluorescence staining. (A–L) Images present the expression in the paraflocculus region of the cerebellum. (A) Lsamp
1a expression is not observable; however (B) Lsamp 1b is highly expressed through molecular and
granular cell layers. (D) Ntm 1a expression is restricted to the Purkinje cell layer whereas (E) Ntm 1b
is observable in the granular cell layer. As with Ntm 1a (G,H) Opcml 1a/1b is expressed in defined
locations of Purkinje cell layers. (K) Negr1 probe is observable in both Purkinje cells and granular cell
layers. (J,K)scheme of cutting planes. Abbreviations: grl, granular layer; ml, molecular layer; PC,
Purkinje cell layer. Scale bar: 300 µm (A,B,D,E,J,K); 100 µm (C,F,I,L).

3. Discussion
The five members of the IgLON family of neuronal cell adhesion molecules carry
molecular cues that guide axon and dendrite development, support the formation of synaptic connections, and promote the refinement of connectivity and plasticity during brain
development. Use of multiple mRNA isoforms through alternative promoter usage is prevalent during embryonic brain development. mRNA isoforms encode a variety of proteins
with diverse cellular and subcellular distribution over development stages, contributing
significantly to a wide range of neuronal functions [4,5,43]. These isoform expression patterns appear to be important for normal brain development, since dysregulation of mRNA
isoform expression is implicated in neurological and neuropsychiatric disorders [44,45].
Transcriptome-wide association studies suggest that isoform-level alterations show wider
pathological effects as compared to gene-level alterations, enabling more precise analyses
of brain function and development than those using solely gene-level analysis [43,45,46].
Our work highlights the selective usage of alternative IgLON promoters in different
developmental stages and in various regions of the central nervous system. We found that
two alternative isoforms-1a and 1b in Lsamp, Ntm and Opcml are differentially expressed
during development, indicating the regulation of alternative promoter usage. Previous
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neuroanatomical mRNA expression studies detected the origins of the diverse spatial
distribution of IgLONs around E12.5–15, a time when neurons establish their circuits
during embryonic brain development [12,41,47–49].Our data are the first to show the
expression of IgLONs as early as E10.5. The earliest expression is detected from Negr1
and from one of the alternative isoforms of Lsamp, Ntm and Opcml in the neuroepithelium
(Supplementary Figure S1). This timing correlates with the neurogenic and expansion
phase of brain development. Soon afterward, complementary expression of alternative
IgLON gene isoforms is seen in the cellular region of newly formed Cajal–Retzius cells
(the first-born neurons from NSCs, formed after the expansion phase), suggesting that
distinct IgLON isoforms play specific roles in the establishment of cortical architecture.
The gradual increase and expansion of IgLONs throughout the developing brain during
embryogenesis in the rodents (E13.5–E17) demonstrate the regionally dependent and
complex cooperational usage of alternative promoters at the time when rapid neurogenesis
is in progress and specific functional brain regions are being delineated. Expression
patterns of IgLONs indicate the involvement during final stages of neurogenesis, when
some of the differentiating daughter cells from NSCs undergo the gliogenesis phase of
development and generate astrocytes, oligodendrocytes, and ependymal cells. Our result
from whole-mount embryo also showed that some promoter-specific IgLONs expression
continues laterally past the CNS and may represent migrating neural crest cells. Indeed,
some of the earliest observations of IgLONs had been on migrating chick neural crest
cells [50] as well as on chick dorsal root ganglia and sympathetic neurons, two trunk neural
crest derivatives [51].
We have shown that IgLON molecules may be responsible for providing the adhesion
differences that mediate the separation of the dorsal and ventral pallium compartments of
the embryonic telencephalon. The telencephalon of amniotes is genetically divided into
four evolutionarily conserved domains, identified as the medial, dorsal, lateral and ventral
pallium [52] and we have shown that the expression of different IgLON isoforms is established in each of these four pallial subdivisions during early embryonic stages. Moreover,
the expression of different IgLON isoforms in the germinal zone of dorsal pallium appears
to participate in the development of the cortical layers. The IgLON isoforms expressions are
clear in the ventricular zone of the lateral and ventral pallium subdivisions, subventricular
zone and extend to developing cortices.
Above the subventricular zone, the crescent-shaped expression of Lsamp uni and Ntm
1a/1b probes appears at E13.5 in the lateral and ventral pallium, marking the boundary
of the putative subplate. These expression domains are opposed with the expression of
the Negr1 domain, which lines the pial side. In addition to the subplate, cells derived
from the lateral pallium contribute to development of the 6b layer of cerebral cortex,
claustrum, and insular cortex, whereas the bed nucleus of stria terminalis, endopiriform
nucleus, piriform cortices, and pallial amygdala are derived from ventral pallium. We
observe both complementary and overlapping expression domains of IgLON alternative
promoters in the primordia of aforementioned structures at E13.5. Importantly, these
expression domains persist throughout the formation of these structures, and they are
maintained in the adult brain. This gradient could be formed by several cell types such as
the radial glial cells or migrating neurons. Determining the identity of these cells is crucial
for understanding how brain regions arise during early neural development, as a similar
gradient pattern of IgLON isoforms expression is observable along the pallial subdomains,
in the insular/perirhinal mesocortex, the three layered allocortex, and the isocortex. This
graded pattern of expression suggests an evolutionarily conserved mechanism, whereby
regional coherence is achieved through the alternative and quantitative expression of cell
adhesion molecules [53,54].
Differences in the isoform-specific expression of IgLONs were evident in the formation
of the histogenetic fields of the hippocampus as it develops from the medial pallium. This
region becomes critical for learning, memory formation, association, and cognition, as well
as for sensorimotor processing, which will become executed in the isocortex (dorsal pallium
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in non-mammals). However, the lateral and ventral pallium derivatives, the claustrum,
piriform cortex and the pallial amygdala, are involved in olfactory processing and control of
emotional and autonomic behavior [55,56]. The observed developmental expression pattern
of IgLONs in these brain substrates corresponds with eventual functional specificities, such
as the regulation of social, emotional, and cognitive behaviors [20,22,34–42].
The development and maintenance of precise and specific neuronal contacts are critical
for the proper functioning of neuronal cells [57], where IgLONs adhesion molecules exhibit
key functions providing a platform for these cell–cell interacting processes. IgLONs are
known to be involved in directing the formation of a variety of neural circuits. For example,
Lsamp is involved in the fasciculation of dopaminergic afferents from the midbrain to the
lateral habenula, thalamic, septo, and intrahippocampal circuits of limbic system circuitry.
Ntm is involved in thalamocortical and pontocerebellar projections, while Negr1 is seen to
be important in cortico-hippocampal circuits [12,18,21,22,34,42,58,59].
Regardless of individual expression patterns, the common peak temporal expression
during early development suggests that the IgLON gene family plays important roles in
many of the major neuro-developmental processes, including neuronal migration, neurite
initiation, neurite outgrowth, axon pathfinding, axon fasciculation, synaptogenesis, myelination, cytoskeletal dynamics, and the maintenance of neuronal networks. Their distinct
and partially overlapping spatial expression indicates that disruptions to the expression or
function of these isoforms could produce additive deleterious effects such as abnormal neuritogenesis and neurogenesis, imbalanced excitatory/inhibitory ratios, and changes in brain
volume. These changes can produce the diverse emotional, cognitive and social behavior
disorders that are observed in the IgLON/sdeficient mice [20–22,34–42] used to model
schizophrenia, autism, learning, and intellectual disabilities. However, the mechanisms
behind these neuropathology are still unknown and needed further investigation.
Negr1 immunolabelling in the cerebellum is localized to the Purkinje cells and clearly
reveals the arborization of their dendrites. Lsamp protein was localized as continuous
puncta in the neurites reaching glia limitans. Similar localization patterns are seen in the glia
limitans with Ntm and Opcml immunolabelling. These observations suggest a possible role
for these IgLONs in the formation and maintenance of the blood-brain-barrier. Subsequent
work is necessary to determine whether functional loss of IgLONs leads to defective
glia limitans. This is particularly relevant as IgLONs have been found to have tumorsuppressive properties in neural and non-neural tissue [60–66]. Furthermore, NEGR1 has
been found to control endothelial integrity in human brain microvessels [67]; LSAMP has
been shown to be implicated in the coronary artery disease and both LSAMP and OPCML
have been shown to be implicated in the epithelial-mesenchymal transition [68,69]. Taken
together, current developmental data are an important addition to the earlier evidence
suggesting that IgLONs are implicated in the evolutionary changes in the brain anatomy
towards complexity including blood-brain-barrier permeability [70].
This paper allows several new questions to be analyzed, as further study is required
to identify the isoform-specific interacting partners of IgLONs in the embryonic brain, the
particular cell types expressing these isoforms, the mechanisms for the promoter-specific
transcriptional regulation, and the molecular mechanisms of neural pathogenesis at the
isoform-, rather than gene-level, resolution.
4. Materials and Methods
4.1. Animals
Wild-type C57BL/6 (Scanbur, Karl-slunde, Denmark) mice were used for in situ
hybridization. Immunohistochemistry was performed on male mice in F2 background
[(129S6/SvEvTac × C57BL/6) × (129S6/SvEvTac × C57BL/6)]. Mice were housed under
standard laboratory conditions of a 12 hr light/dark cycle with lights on at 7:00 a.m., and
they had ad libitum access to food (R70, Lactamin AB, Vadstena, Sweden) and water.
Mice were mated and the presence of a vaginal plug was considered to be embryonic (E)
day 0.5. Breeding and housing of the mice was conducted at the animal facility of the
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Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
All animal procedures were performed in accordance with the European Communities
Directive (86/609/EEC) and permit (No.29, 28 April 2014) from the Estonian National
Board of Animal Experiments.
4.2. In situ Hybridization
The Lsamp 1a and universal (uni) probes were prepared as described in [41]. Mouse
cDNA fragment specific for Ntm 1a (285 bp), Ntm 1b (500bp), Opcml 1a (492 bp), Opcml 1b
(514 bp) and Negr1 (650 bp) transcripts were cloned from a cDNA pool of C57BL/6 mouse
brain and inserted into pBluescript KS+ vector (Stratagene, La Jolla, CA). We used the
following primers (containing restriction sites):
Ntm1a For TATAGCGGCCGCGAGTATGAGTGGAGATAATTACGGA
Ntm1a Rev TATAGTCGACCTTGGAAGAGGCACAGAGCC
Ntm1b For TATAGCGGCCGCGCTGGATTCAACCCAGCCAC
Ntm1b Rev TATAGTCGACGTGGGTACAAGGAATAGCAGCC
Opcml1a For TATAGCGGCCGCGGTGTGCCCATGCGAAGCAC
Opcml1a Rev TATAGTCGACGGATGAAGAGCAGGGCAGTG
Opcml1b For TATAGCGGCCGCTCCTTTCTGTCAGAGACACTTGC
Opcml1b Rev TATAGTCGACTGGGTACAAGGAATAGCAGCCTG
Negr1 For TATAGCGGCCGCATGGTGCTCCTGGCGCAGG
Negr1 Rev TATAGTCGACCAGCCTGGTCCCTTGTAATTCCAT
The mouse brains were dissected immediately after decapitation and fixed for 4 days
in cold 4% PFA (Acros Organics, Ward Hill, MA, U.S.A)/PBS (pH 7.4). In newborn and
adult mice, one temporal lobe was removed to allow better access to the fixative. The mouse
brains were cryoprotected for 2 days in 30% sucrose (AppliChem, Dresden, Germany) in 4%
PFA/PBS, and stored at −80 ◦ C until sectioning. The non-radioactive in situ hybridization
on 40-µm free-floating mouse (E17, P0, adult) brain cryo-sections using digoxigenin-UTP
(Roche, Indianapolis, IN, U.S.A)-labeled RNA probes was performed as described in [71].
For the whole-mount in situ hybridization, the embryos were dissected in cold PBS
and fixed in cold 4% PFA/PBS (pH 7.4) for 4 days. Fixed embryos were washed with
PBS containing 0.25%, Tween 20 (Naxo, Tartu, Estonia) (PBST), followed by dehydrated
in 25%, 50%, 75% methanol (Naxo, Tartu, Estonia) in PBST, and 100% methanol for 5 min
at each step. Thereafter, the samples were rehydrated with methanol/PBST in reverse
series, PBST washing and treatment with 10 µg/mL of proteinase K (AppliChem, Dresden,
Germany) in PBST for 10 min is followed by washing with 2mg/mL of glycine (Naxo, Tartu,
Estonia) in PBST. Embryos were then refixed in 4% PFA/0.2% glutaraldehyde (AppliChem,
Dresden, Germany) for 20 min. After washing with PBST embryos were incubated in a
prehybridization solution containing 50% formamide (AppliChem, Dresden, Germany)/5X
SSC (pH 5) overnight at 65 ◦ C with gentle agitation.
For hybridization RNA probe (500ng/mL) was added to the prehybridization solution
and incubated over 3 days with gentle agitation at 65 ◦ C. Samples were washed as follows:
thrice with 1% SDS/5X SSC/50% formamide for 30 min at 65 ◦ C; thrice with 2X SSC/50%
formamide for 30 min and then overnight at 65 ◦ C; thrice with TBST (0.15M NaCl: 0.1M
Tris-HCl, pH7.5; 0.1% Tween-20) for 10 min each and incubated two days at 4 ◦ C in anti-DIGAP-conjugated antibody (1:1000, Roche, Indianapolis, IN, USA)/TBST. Unbound antibody
was removed by three 10 min and five 60 min washes in TBST. Embryos were washed
thrice with NTMT (0.1M NaCl; 0.1M Tris-HCl, pH9.5; 50 mM MgCl2; 0.1% Tween-20) for
10 min followed by incubation in the staining solution (BM-Purple, Roche, Indianapolis,
IN, USA).
For cutting 50-µm vibratome sections, the stained (E10.5, 13.5) embryos were inserted
into 1 mL of 0.5 % gelatine Sigma Aldrich, Taufkirchen, Germany/30 % BSA Sigma Aldrich,
Taufkirchen, Germany/20 % sucrose (AppliChem, Dresden, Germany)/PBS, wherein
140 µL of 25 % glutaraldehyde (AppliChem, Dresden, Germany) was added immediately
before insertion and incubated for 10 min. The sections were mounted into 70 % glycerol
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and micro photographed using an Olympus BX61 microscope equipped with an Olympus
DX70 CCD camera (Olympus, Hamburg, Germany).
4.3. X-Gal Staining
Free-floating sections were stained overnight for X-Gal staining for detecting the distribution of Lsamp 1b promoter was performed as described previously [72]. Alternatively,
whole brains were incubated in X-Gal staining solution immediately after fixation. After
X-Gal staining, tissue was incubated in 2% PFA solution in PB to give it a pale white
appearance. Sections were transferred to gelatinized glass slides and mounted with Pertex
(Histolab, Malmö, Sweden)
4.4. Immunohistochemistry
Brains of adult mice were dissected and fixed in 4% PFA for 4–5 days followed by
cryoprotection with 30% sucrose in PBS, frozenand sectioned at 40 µm. Free-floating
coronal sections from the cerebellar paraflocculus region were permeabilized, blocked and
immunostained with primary antibodies: mouse anti-Lsamp (1:200, DSHB; 2G9), goat
anti-Opcml (1:200, Santa Cruz Biotechnology, Heidelberg, Garmany; sc-26121; this product
has been discontinued), mouse anti-Negr1 (1:100, Santa Cruz Biotechnology, Heidelberg,
Garmany; sc-393293), mouse anti-Ntm (1:200, Santa Cruz Biotechnology, Heidelberg,
Garmany; sc390941) followed by secondary antibodies: Rhodamine (TRITC)-AffiniPure
Donkey Anti-Mouse IgG (H+L) (1:500, Jackson ImmunoResearch Labs, West Grove, PA,
USA; 715-025-150) and Rhodamine Red-X-AffiniPure Fab Fragment Rabbit Anti-Goat IgG
(H+L) antibody (1:500, Jackson ImmunoResearch Labs, West Grove, PA, USA; 305-297-003).
Nuclei were stained with 5 µg/mL Bisbenzimide H 33258 (Hoechst 33258, Sigma Aldrich,
Taufkirchen, Germany)/PBS for 15 min. Subsequently, sections were washed with PBS and
mounted with Fluoromount mounting medium (Sigma Aldrich, Taufkirchen, Germany),
and covered with a 0.17-mm coverslip (Deltalab, Barcelona, Spain). Specificity of the
immunohistochemistry was determined by incubations without the primary antibodies.
Fluorescent images were obtained with the Olympus FV1200MPE (Olympus, Hamburg,
Germany) laser scanning confocal microscope. Abbreviations in all the figures representing
anatomical data have been adopted from the mouse brain atlas [73].
5. Conclusions
In conclusion, we have shown that IgLON members are involved in, and perhaps
orchestrate, the early events of pallium development. The complexity of the spatiotemporal
distribution patterns of the IgLONs is intimately linked to regional brain organization and
to the emergence of functional distinctions in the developing nervous system. Distinct
isoform-specific expression domains and gradients suggest the importance of IgLONs
alternative promoter usage in helping coordinate the complexly integrated functions of
neural cell proliferation, differentiation, and morphogenesis into the more specialized
substructures.Importantly, IgLON expression patterns (1) may be responsible for creating
the anatomical and functional boundaries between regions (which may then be stabilized
by other molecules), (2) may help stabilize pre-existing boundaries between anatomical and
functional regions, or (3) may be a consequence of the anatomical and functional regions,
perhaps acting as tumor suppressing inhibitors of cell proliferation and apoptosis. Indeed,
it would not be surprising if IgLONs were performing different roles in different brain
regions. The IgLON superfamily may have evolved the alternative promoter system to
produce necessary mRNA isoforms from single gene loci in the specific histogenetic fields
at specific times.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ijms22136955/s1, Figure S1: In situmRNA hybridization displaying Lsamp 1a, Negr1, Ntm
1a, andOpcml 1b at E10.5 coronal sections. Figure S2. Expression from IgLON family alternative
promoters at E17 forebrain images at high magnification.

Int. J. Mol. Sci. 2021, 22, 6955

17 of 20

Author Contributions: Conceptualization, K.S. (Katyayani Singh), M.-A.P., T.J. and K.L.; Methodology,
K.S. (Katyayani Singh), T.J., K.S. (Kadri Seppa), M.J.; T.T.; K.L. Software, T.J.; K.S. (Katyayani Singh);
Validation, K.S. (Katyayani Singh), T.J., K.L. and M.-A.P.; Formal analysis, K.S. (Katyayani Singh),
T.J., M.-A.P., K.L.; Resources, M.-A.P., E.V., Writing—original draft preparation, K.S. (Katyayani Singh),
T.J., S.F.G., M.-A.P. and K.L.; Writing—review and editing, all authors; All authors have read and
agreed to the published version of the manuscript.
Funding: This study was supported by an institutional investigation grant IUT20-41, personal
investigation grant PUT129and personal research funding team grant project PRG685 from the
Estonian Research Council.The Estonian Research Council-European Union Regional Developmental
Fund Mobilitas Pluss Program No. MOBTT77. This research was also supported by the European
Union through the European Regional Development Fund (Project No. 2014–2020.4.01.15-0012)
to Centre of Excellence for Genomics and Translational Medicine (TK142) and from the European
Union’s Horizon 2020 research and innovation program under grant agreement 692202.
Institutional Review Board Statement: All animal procedures in this study were performed in accordance with the European Communities Directive (2010/63/EU) and permit (No. 29, 28 April 2014)
from the Estonian National Board of Animal Experiments. In addition, the use of mice was conducted
in accordance with the regulations and guidelines approved by the Laboratory Animal Centre at the
Institute of Biomedicine and Translational Medicine. This article does not contain any studies with
human participants or human samples.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Acknowledgments: We are extremely grateful to Luis Puelles for the valuable comments provided
during the preparation of this manuscript (result validation).
Conflicts of Interest: The authors declare no conflict of interest.

References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.

12.
13.
14.
15.

Mukhtar, T.; Taylor, V. Untangling Cortical Complexity During Development. J. Exp. Neurosci. 2018, 12, 1179069518759332.
[CrossRef] [PubMed]
Lee, H.K.; Lee, H.S.; Moody, S.A. Neural transcription factors: From embryos to neural stem cells. Mol. Cells 2014, 37, 705–712.
[CrossRef] [PubMed]
Nieuwenhuys, R. Principles of current vertebrate neuromorphology. Brain Behav. Evol. 2017, 90, 117–130. [CrossRef] [PubMed]
Davuluri, R.V.; Suzuki, Y.; Sugano, S.; Plass, C.; Huang, T.H. The functional consequences of alternative promoter use in
mammalian genomes. Trends Genet. 2008, 24, 167–177. [CrossRef]
Wang, E.T.; Sandberg, R.; Luo, S.; Khrebtukova, I.; Zhang, L.; Mayr, C.; Kingsmore, S.F.; Schroth, G.P.; Burge, C.B. Alternative
isoform regulation in human tissue transcriptomes. Nature 2008, 456, 470–476. [CrossRef]
Kalsotra, A.; Cooper, T.A. Functional consequences of developmentally regulated alternative splicing. Nat. Rev. Genet. 2011, 12,
715–729. [CrossRef]
Baralle, F.E.; Giudice, J. Alternative splicing as a regulator of development and tissue identity. Nat. Rev. Mol. Cell Boil. 2017, 18,
437–451. [CrossRef] [PubMed]
Pimenta, A.F.; Levitt, P. Characterization of the genomic structure of the mouse limbic system-associated membrane protein
(Lsamp) gene. Genomics 2004, 83, 790–801. [CrossRef]
Vanaveski, T.; Singh, K.; Narvik, J.; Eskla, K.-L.; Visnapuu, T.; Heinla, I.; Jayaram, M.; Innos, J.; Lilleväli, K.; Philips, M.-A.; et al.
Promoter-specific expression and genomic structure of IgLON family genes in mouse. Front. Neurosci. 2017, 11, 38. [CrossRef]
Salzer, J.L.; Rosen, C.L.; Struyk, A.F. GPI anchored protein in neural cell adhesion. Adv. Mol. Cell. Biol. 1996, 16, 193–222.
Sharma, K.; Schmitt, S.; Bergner, C.; Tyanova, S.; Kannaiyan, N.; Manrique-Hoyos, N.; Kongi, K.; Cantuti, L.; Hanisch, U.-K.;
Philips, A.-M.; et al. Cell type- and brain region-resolved mouse brain proteome. Nat. Neurosci. 2015, 18, 1819–1831. [CrossRef]
[PubMed]
Struyk, A.F.; Canoll, P.D.; Wolfgang, M.J.; Rosen, C.L.; D’Eustachio, P.; Salzer, J.L. Cloning of neurotrimin defines a new subfamily
of differentially expressed neural cell adhesion molecules. J. Neurosci. 1995, 15, 2141–2156. [CrossRef] [PubMed]
Gil, O.D.; Zhang, L.; Chen, S.; Ren, Y.Q.; Pimenta, A.; Zanazzi, G.; Hillman, D.; Levitt, P.; Salzer, J.L. Complementary Expression
and Heterophilic Interactions between IgLON Family Members Ntm and LAMP. J. Neurobiol. 2002, 51, 190–204. [CrossRef]
Hashimoto, T.; Maekawa, S.; Miyata, S. IgLON cell adhesion molecules regulate synaptogenesis in hippocampal neurons. Cell.
Biochem. Funct. 2009, 27, 496–498. [CrossRef]
Akeel, M.; McNamee, C.J.; Youssef, S.; Moss, D. DIgLONs inhibit initiation of neurite outgrowth from forebrain neurons via an
IgLON-containing receptor complex. Brain Res. 2011, 1374, 27–35. [CrossRef]

Int. J. Mol. Sci. 2021, 22, 6955

16.
17.

18.

19.
20.

21.

22.
23.
24.

25.
26.

27.

28.

29.
30.
31.

32.

33.

34.

35.
36.
37.
38.

18 of 20

Reed, J.; McNamee, C.; Rackstraw, S.; Jenkins, J.; Moss, D. Diglons are heterodimeric proteins composed of IgLON subunits, and
diglon-CO inhibits neurite outgrowth from cerebellar granule cells. J. Cell. Sci. 2004, 117, 3961–3973. [CrossRef]
Heinla, I.; Leidmaa, E.; Kongi, K.; Pennert, A.; Innos, J.; Nurk, K.; Tekko, T.; Singh, K.; Vanaveski, T.; Reimets, R.; et al. Gene
expression patterns and environmental enrichment-induced effects in the hippocampi of mice suggest importance of Lsamp in
plasticity. Front. Neurosci. 2015, 9, 205. [CrossRef] [PubMed]
Schmidt, E.R.; Brignani, S.; Adolfs, Y.; Lemstra, S.; Demmers, J.; Vidaki, M.; Donahoo, A.-L.S.; Lillevälli, K.; Vasar, E.; Richards,
L.K.; et al. Subdomain-mediated axon-axon signaling and chemoattraction cooperate to regulate afferent innervation of the
lateral habenula. Neuron 2014, 83, 372–387. [CrossRef] [PubMed]
Sanz, R.; Ferraro, G.B.; Fournier, A.E. IgLON cell adhesion molecules are shed from the cell surface of cortical neurons to promote
neuronal growth. J. Biol. Chem. 2015, 290, 4330–4342. [CrossRef]
Singh, K.; Lillevali, K.; Gilbert, S.F.; Bregin, A.; Narvik, J.; Jayaram, M.; Rahi, M.; Innos, J.; Kaasik, A.; Vasar, E.; et al. The combined
impact of IgLON family proteins Lsamp and Neurotrimin on developing neurons and behavioral profiles in mouse. Brain. Res.
Bull. 2018, 140, 5–18. [CrossRef]
Szczurkowska, J.; Pischedda, F.; Pinto, B.; Managò, F.; Haas, C.A.; Summa, M.; Bertorelli, R.; Papaleo, F.; Schäfer, M.; Piccoli, G.;
et al. NEGR1 and FGFR2 cooperatively regulate cortical development and core behaviours related to autism disorders in mice.
Brain 2018, 141, 2772–2794. [CrossRef] [PubMed]
Noh, K.; Lee, H.; Choi, T.Y.; Yoo, J.; Kim, S.-J.; Kim, H.; Kim, J.Y.; Jahng, J.W.; Lee, S.; Choi, S.-Y.; et al. Negr1 controls adult
hippocampal neurogenesis and affective behaviors. Mol. Psychiatry 2019, 24, 1189–1205. [CrossRef] [PubMed]
Must, A.; Tasa, G.; Lang, A.; Vasar, E.; Kõks, S.; Maron, E.; Väli, M. Association of limbic system-associated membrane protein
(LSAMP) to male completed suicide. BMC Med. Genet. 2008, 9, 34. [CrossRef] [PubMed]
Behan, A.T.; Byrne, C.; Dunn, M.J.; Cagney, G.; Cotter, D.R. Proteomic analysis of membrane micro domain-associated proteins in
the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein
expression. Mol. Psychiatry 2009, 14, 601–613. [CrossRef] [PubMed]
Pan, Y.; Wang, K.S.; Aragam, N. NTM and NR3C2 polymorphisms influencingintelligence: Family-based association studies,
Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35, 154–160. [CrossRef]
Sabater, L.; Gaig, C.; Gelpi, E.; Bataller, L.; Lewerenz, J.; Torres-Vega, E.; Contreras, A.; Giometto, B.; Compta, Y.; Embid, C.; et al.
A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies
to IgLON5: A case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014, 13, 575–586. [CrossRef]
Hyde, C.L.; Nagle, M.W.; Tian, C.; Chen, X.; Paciga, S.A.; Wendland, J.R.; Tung, J.Y.; Hinds, D.A.; Perlis, R.H.; Winslow, A.R.
Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nat. Genet. 2016, 48,
1031–1036. [CrossRef]
Karis, K.; Eskla, K.-L.; Kaare, M.; Täht, K.; Tuusov, J.; Visnapuu, T.; Innos, J.; Jayaram, M.; Timmusk, T.; Weickert, C.S.; et al. Altered
Expression Profile of IgLON Family of Neural Cell Adhesion Molecules in the Dorsolateral Prefrontal Cortex of Schizophrenic
Patients. Front. Mol. Neurosci. 2018, 11, 8. [CrossRef]
Grove, J.; Ripke, S.; Als, T.D.; Mattheisen, M.; Walters, R.K.; Won, H.; Pallesen, J.; Agerbo, E.; Andreassen, O.A.; Anney, R.; et al.
Identification of common genetic risk variants for autism spectrum disorder. Nat. Genet. 2019, 51, 431–444. [CrossRef]
Narita, A.; Nagai, M.; Mizuno, S.; Ogishima, S.; Tamiya, G.; Ueki, M.; Sakurai, R.; Makino, S.; Obara, T.; Ishikuro, M.; et al.
Clustering by phenotype and genome-wide association study in autism. Transl. Psychiatry 2020, 10, 290. [CrossRef]
Pinto, D.; Delaby, E.; Merico, D.; Barbosa, M.; Merikangas, A.; Klei, L.; Thiruvahindrapuram, B.; Xu, X.; Ziman, R.; Wang, Z.; et al.
Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am. J. Hum. Genet. 2014, 94, 677–694.
[CrossRef]
Davies, G.; Lam, M.; Harris, S.E.; Trampush, J.W.; Luciano, M.; Hill, W.D.; Hagenaars, S.P.; Ritchie, S.J.; Marioni, R.E.; FawnsRitchie, C.; et al. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nat.
Commun. 2018, 9, 2098. [CrossRef]
Lee, J.J.; Wedow, R.; Okbay, A.; Kong, E.; Maghzian, O.; Zacher, M.; Nguyen-Viet, T.A.; Bowers, P.; Sidorenko, J.; Linnér, R.K.;
et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million
individuals. Nat. Genet. 2018, 50, 1112–1121. [CrossRef]
Singh, K.; Jayaram, M.; Kaare, M.; Leidmaa, E.; Jagomäe, T.; Heinla, I.; Hickey, M.A.; Kaasik, A.; Schäfer, M.K.; Innos, J.; et al.
Neural cell adhesion molecule Negr1 deficiency in mouse results in structural brain endophenotypes and behavioral deviations
related to psychiatric disorders. Sci. Rep. 2019, 9, 5457. [CrossRef]
Innos, J.; Philips, M.A.; Leidmaa, E.; Heinla, I.; Raud, S.; Reemann, P.; Plaas, M.; Nurk, K.; Kurrikoff, K.; Matto, V.; et al. Lower
anxiety and a decrease in agonistic behaviour in Lsamp-deficient mice. Behav. Brain Res. 2011, 217, 21–31. [CrossRef] [PubMed]
Innos, J.; Philips, M.A.; Raud, S.; Lilleväli, K.; Kõks, S.; Vasar, E. Deletion of theLsamp gene lowers sensitivity to stressful
environmental manipulations in mice. Behav. Brain Res. 2012, 228, 74–81. [CrossRef]
Innos, J.; Leidmaa, E.; Philips, M.A.; Sütt, S.; Alttoa, A.; Harro, J.; Kõks, S.; Vasar, E. Lsamp−/− mice display lower sensitivity to
amphetamine and have elevated 5-HT turnover. Biochem. Biophys. Res. Commun. 2013, 430, 413–418. [CrossRef] [PubMed]
Bregin, A.; Mazitov, T.; Aug, I.; Philips, M.A.; Innos, J.; Vasar, E. Increased sensitivity to psychostimulants and GABAergic drugs
in Lsamp-deficient mice. Pharmacol. Biochem. Behav. 2019, 183, 87–97. [CrossRef] [PubMed]

Int. J. Mol. Sci. 2021, 22, 6955

39.

40.
41.

42.

43.
44.

45.

46.

47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.

61.

62.
63.

19 of 20

Bregin, A.; Kaare, M.; Jagomäe, T.; Karis, K.; Singh, K.; Laugus, K.; Innos, J.; Leidmaa, E.; Heinla, I.; Visnapuu, T.; et al. Expression
and impact of Lsamp neural adhesion molecule in the serotonergic neurotransmission system. Pharmacol. Biochem. Behav. 2020,
198, 173017. [CrossRef] [PubMed]
Mazitov, T.; Bregin, A.; Philips, M.A.; Innos, J.; Vasar, E. Deficit in emotional learning in neurotrimin knockout mice. Behav. Brain
Res. 2017, 28, 311–318. [CrossRef]
Philips, M.A.; Lilleväli, K.; Heinla, I.; Luuk, H.; Hundahl, C.A.; Kongi, K.; Vanaveski, T.; Tekko, T.; Innos, J.; Vasar, E. Lsampis
implicated in the regulation of emotional and social behavior by use of alternative promoters in the brain. Brain Struct. Funct.
2015, 220, 1381–1393. [CrossRef]
Singh, K.; Loreth, D.; Pottker, B.; Hefti, K.; Innos, J.; Schwald, K.; Hengstler, H.; Menzel, L.; Sommer, C.J.; Radyushkin, K.; et al.
Neuronal growth and behavioral alterations in mice deficient for the psychiatric disease-associated Negr1 gene. Front. Mol.
Neurosci. 2018, 11, 30. [CrossRef]
Chau, K.; Zhang, P.; Urresti, J.; Amar, M.; Pramod A., B.; Thomas, A.; Corominas, R.; Lin, G.N.; Iakoucheva, L. Isoform
transcriptome of developing human brain provides new insights into autism risk variants. bioRxiv 2020. [CrossRef]
Ray, T.A.; Cochran, K.; Kozlowski, C.; Wang, J.; Alexander, G.; Cady, M.A.; Spencer, W.J.; Ruzycki, P.A.; Clark, B.S.; Laeremans, A.;
et al. Comprehensive identification of mRNA isoforms reveals the diversity of neural cell-surface molecules with roles in retinal
development and disease. Nat. Commun. 2020, 11, 3328. [CrossRef] [PubMed]
Gandal, M.J.; Zhang, P.; Hadjimichael, E.; Walker, R.L.; Chen, C.; Liu, S.; Won, H.; van Bakel, H.; Varghese, M.; Wang, Y.;
et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science 2018, 362, eaat8127.
[CrossRef]
Li, M.; Santpere, G.; Imamura Kawasawa, Y.; Evgrafov, O.V.; Gulden, F.O.; Pochareddy, S.; Sunkin, S.M.; Li, Z.; Shin, Y.; Zhu, Y.;
et al. Integrative functional genomic analysis of human brain development and neuropsychiatric risks. Science 2018, 362, eaat7615.
[CrossRef]
Hachisuka, A.; Nakajima, O.; Yamazaki, T.; Sawada, J. Developmental expression of opioid-binding cell adhesion molecule
(OBCAM) in rat brain. Brain Res. Dev. Brain Res. 2000, 122, 183–191. [CrossRef]
Schäfer, M.; Bräuer, A.U.; Savaskan, N.E.; Rathjen, F.G.; Brümmendorf, T. Neurotractin/kilon promotes neurite outgrowth and is
expressed on reactive astrocytes after entorhinal cortex lesion. Mol. Cell. Neurosci. 2005, 29, 580–590. [CrossRef]
Pimenta, A.F.; Reinoso, B.S.; Levitt, P. Expression of the mRNAs encoding the limbic system-associated membrane protein
(LAMP): II Fetal rat brain. J. Comp. Neurol. 1996, 375, 289–302. [CrossRef]
Kimura, Y.; Katoh, A.; Kaneko, T.; Takahama, K.; Tanaka, H. Two members of the IgLON family are expressed in a restricted
region of the developing chick brain and neural crest. Dev. Growth Differ. 2001, 43, 257–263. [CrossRef]
Lodge, A.P.; Howard, M.R.; McNamee, C.J.; Moss, D.J. Co-localisation, heterophilic interactions and regulated expression of
IgLON family proteins in the chick nervous system. Brain Res. Mol. Brain Res. 2000, 82, 84–94. [CrossRef]
Montiel, J.F.; Aboitiz, F. Pallial patterning and the origin of the isocortex. Front. Neurosci. 2015, 9, 377. [CrossRef] [PubMed]
Foty, R.; Steinberg, M.S. The differential adhesion hypothesis: A direct evaluation. Dev. Biol. 2005, 278, 255–263. [CrossRef]
[PubMed]
Tsai, T.Y.; Sikora, M.; Xia, P.; Colak-Champollion, T.; Knaut, H.; Heisenberg, C.P.; Megason, S.G. An adhesion code ensures robust
pattern formation during tissue morphogenesis. Science 2020, 370, 113–116. [CrossRef]
Binks, D.; Watson, C.; Puelles, L. A Re-evaluation of the Anatomy of the Claustrum in Rodents and Primates—Analyzing the
Effect of Pallial Expansion. Front. Neuroanat. 2019, 13, 34. [CrossRef] [PubMed]
Butler, A.B. The evolution of the dorsal pallium in the telencephalon of amniotes: Cladistic analysis and a new hypothesis. Brain
Res. Brain Res. Rev. 1994, 19, 66–101. [CrossRef]
Lodato, S.; Arlotta, P. Generating neuronal diversity in the mammalian cerebral cortex. Annu. Rev. Cell Dev. Biol. 2015, 31, 699–720.
[CrossRef]
Keller, F.; Rimvall, K.; Barbe, M.F.; Levitt, P. A membrane glycoprotein associated with the limbic system mediates the formation
of the septo-hippocampal pathway in vitro. Neuron 1989, 3, 551–561. [CrossRef]
Mann, F.; Zhukareva, V.; Pimenta, A.; Levitt, P.; Bolz, J. Membrane-associated molecules guide limbic and nonlimbic thalamocortical projections. J. Neurosci. 1998, 18, 9409–9419. [CrossRef]
Chen, J.; Lui, W.-O.; Vos, M.D.; Clark, G.J.; Takahashi, M.; Schoumans, J.; Khoo, S.K.; Petillo, D.; Lavery, T.; Sugimura, J.; et al. The
t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell 2003, 4, 405–413.
[CrossRef]
Kresse, S.H.; Ohnstad, H.O.; Paulsen, E.B.; Bjerkehagen, B.; Szuhai, K. LSAMP, a novel candidate tumor suppressor gene in
human osteosarcomas, identified by array comparative genomic hybridization. Genes Chromosom. Cancer 2009, 693, 679–693.
[CrossRef]
Takita, J.; Chen, Y.; Okubo, J.; Sanada, M.; Adachi, M.; Ohki, K.; Nishimura, R.; Hanada, R.; Igarashi, T.; Hayashi, Y.; et al.
Aberrations of NEGR1 on 1p31 and MYEOV on 11q13 in neuroblastoma. Cancer Sci. 2011, 102, 1645–1650. [CrossRef] [PubMed]
Tsou, J.A.; Galler, J.S.; Siegmund, K.D.; Laird, P.W.; Turla, S.; Cozen, W.; Hagen, J.A.; Koss, M.N.; Laird-Offringa, I.A. Identification
of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol. Cancer 2007, 6, 70. [CrossRef]
[PubMed]

Int. J. Mol. Sci. 2021, 22, 6955

64.

65.
66.

67.

68.
69.

70.
71.

72.
73.

20 of 20

Anglim, P.P.; Galler, J.S.; Koss, M.N.; Hagen, J.A.; Turla, S.; Campan, M.; Weisenberger, D.J.; Laird, P.W.; Siegmund, K.D.;
Laird-Offringa, I.A. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer.
Mol. Cancer 2008, 7, 62. [CrossRef]
Cui, Y.; Ying, Y.; van Hasselt, A.; Ng, K.M.; Yu, J.; Zhang, Q.; Jin, J.; Liu, D.; Rhim, J.S.; Rha, S.Y.; et al. OPCML is a broad tumor
suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS ONE 2008, 3, e2990. [CrossRef]
Pasic, I.; Shlien, A.; Durbin, A.D.; Stavropoulos, D.J.; Baskin, B.; Ray, P.N.; Novokmet, A.; Malkin, D. Recurrent focal copy-number
changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in
osteosarcoma. Cancer Res. 2010, 70, 160–171. [CrossRef]
Zhang, Q.; Liu, C.; Li, Q.; Li, J.; Wu, Y.; Liu, J. MicroRNA-25-5p counteracts oxidized LDL-induced pathological changes by
targeting neuronal growth regulator 1 (NEGR1) in human brain micro-vessel endothelial cells. Biochimie 2019, 165, 141–149.
[CrossRef]
Antony, J.; Zanini, E.; Birtley, J.; Gabra, H.; Recchi, C. Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.
Cancer Gene Ther. 2021, 28, 18–26. [CrossRef]
Hua, X.; Liu, Z.; Zhou, M.; Tian, Y.; Zhao, P.P.; Pan, W.-H.; Li, C.-L.; Huang, X.-X.; Liao, Z.-X.; Xian, Q.; et al. LSAMP-AS1 binds to
microRNA-183-5p to suppress the progression of prostate cancer by up-regulating the tumor suppressor DCN. EBioMedicine 2019,
50, 178–190. [CrossRef]
Kubick, N.; Brösamle, D.; Mickael, M.E. Molecular Evolution and Functional Divergence of the IgLON Family. Evol. Bioinform.
Online 2018, 14, 1176934318775081. [CrossRef]
Tekko, T.; Lilleväli, K.; Luuk, H.; Sütt, S.; Truu, L.; Örd, T.; Möls, M.; Vasar, E. Initiation and developmental dynamics of Wfs1
expression in the context of neural differentiation and ER stress in mouse forebrain. Int. J. Dev. Neurosci. 2014, 35, 80–88.
[CrossRef] [PubMed]
Luuk, H.; Kõks, S.; Plaas, M.; Hannibal, J.; Rehfeld, J.F.; Vasar, E. Distribution of Wfs1 protein in the central nervous system of the
mouse and its relation to clinical symptoms of the Wolfram syndrome. J. Comp. Neurol. 2008, 509, 642–660. [CrossRef] [PubMed]
Franklin, K.B.J.; Paxinos, G. The Mouse Brain in Stereotaxic Coordinates; Academic Press: London, UK, 1997.

